# Kunshan RiboQuark Pharmaceutical Technology Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kunshan-riboquark-pharmaceutical-technology

- Industry: Pharmaceuticals
- Headquarters: Kunshan, China
- Total disclosed funding: $7.4M
- Latest round: Series A (Dec 31, 2013)
- Investors on record: 4

## About

Founded in 2012 and based in Kunshan, China, Kunshan RiboQuark Pharmaceutical Technology Co operates as a clinical stage pharmaceutical company. The firm is jointly established by Suzhou Ribo Life Science and Quark Pharmaceuticals. In December 2013, the firm raised CNY 45 million in series A funding.

The company's main product is the ophthalmic drug QPI-1007. QPI-1007 is used to treat eye diseases such as non-arteritic anterior ischemic optic neuropathy and acute angle-closure glaucoma.

The company’s revenue is generated by providing ophthalmic drugs.

## Funding rounds

- Series A, Dec 31, 2013, $7.4M — SBI Holdings, BVCF Capital, Kunshan Industrial Technology Research Institute Investment Co., Ltd., Kunshan Hongtu Hi-tech Venture Capital Management Co., Ltd

## Investors

- SBI Holdings — Series A
- BVCF Capital — Series A
- Kunshan Industrial Technology Research Institute Investment Co., Ltd. — Series A
- Kunshan Hongtu Hi-tech Venture Capital Management Co., Ltd — Series A